innvitation to ONE

1. INVITATION
19–20 November 2010
Macdonald Berystede Hotel
Ascot, UK
The ONE Programme
Optic Nerve Evaluation
Did you know that the overall diagnostic accuracy of judging optic disc photographs for glaucoma by European general
ophthalmologists is only 80.5%?1 Recently, the European Optic Disc Assessment Trial (EODAT) revealed a large variability
in diagnostic accuracy among physicians, with common imaging devices outperforming most ophthalmologists.1
We are pleased to invite you to take part in the ONE Programme – an innovative workshop providing practical training to
improve optic disc assessment for glaucoma diagnosis. The ONE Programme uses 3D technology to view images from the
EODAT, and includes dynamic plenary and workshop sessions designed to support and facilitate advanced optic disc assessment.
The ONE Programme will be led by a distinguished faculty of European experts, including investigators of the EODAT, and will
be chaired by Dr Hans Lemij (Rotterdam Eye Hospital, Rotterdam, the Netherlands).
In addition, we are delighted to be joined by Professor Thierry Zeyen who is currently leading the European Glaucomatous
Optic Disc Assessment for Progression (EGODAP)* trial. EGODAP is a new study investigating the impact of training on
physicians’ ability to assess optic disc images for signs of glaucoma progression. Professor Zeyen invites you to take part in
this exciting new trial and take the next step in improving the monitoring of patients with glaucoma.
As you are an expert in your field, we would value your involvement in the ONE Programme and we hope you will be able to
join us for what promises to be an informative, innovative, and interactive meeting.
Faculty
Hans Lemij, the Netherlands (Chair) Fotis Topouzis, Greece
David Garway-Heath, UK Ananth Viswanathan, UK
Roger Hitchings, UK Thierry Zeyen, Belgium
Reference
1. Reus NJ et al. Ophthalmology. 2010;117:717–723.
*The EGODAP trial is being run completely independently from Pfizer Ophthalmics by ProfessorThierry Zeyen from the Department of Ophthalmology,
University Hospitals Leuven, Leuven, Belgium.The trial is funded by an Investigator-Initiated Research grant from Pfizer Ltd.
EUGC180e July 2010